Boston Scientific Corporation $BSX Shares Purchased by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in Boston Scientific Corporation by 31.6%, holding a total of 3,145,777 shares valued at approximately $337.9 million.
• Boston Scientific reported a quarterly earnings per share of $0.75, surpassing analysts' expectations of $0.72, with revenues reaching $5.06 billion.
• Insider selling activity is evident, with EVP Arthur C. Butcher and Director Yoshiaki Fujimori reducing their stakes significantly, as insiders sold a total of 174,214 shares worth nearly $18 million over the last ninety days.

Robeco Institutional Asset Management B.V. raised its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 31.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,145,777 shares of the medical equipment provider's stock after purchasing an additional 756,199 shares during the period. Robeco Institutional Asset Management B.V. owned 0.21% of Boston Scientific worth $337,888,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BSX. 1248 Management LLC purchased a new position in Boston Scientific during the first quarter valued at $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the first quarter worth about $27,000. Sound Income Strategies LLC lifted its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock worth $27,000 after buying an additional 120 shares in the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Boston Scientific in the second quarter worth about $37,000. Finally, Activest Wealth Management lifted its stake in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock worth $38,000 after buying an additional 373 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of BSX opened at $95.78 on Thursday. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The stock has a market cap of $141.91 billion, a PE ratio of 57.01, a P/E/G ratio of 2.35 and a beta of 0.61. The firm has a 50-day simple moving average of $103.30 and a two-hundred day simple moving average of $102.08. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the business earned $0.62 earnings per share. The business's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Truist Financial raised their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a research note on Wednesday. Robert W. Baird raised their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research report on Wednesday. Needham & Company LLC restated a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Wednesday. Finally, Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $120.67.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares of the company's stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.